Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem

References

• PoulsenJLBrockCOlesenAENilssonMDrewesAMClinical potential of naloxegol in the management of opioid-induced bowel dysfunctionClin Exp Gastroenterol2014734535825278772
   PubMedGoogle Scholar
• KumarLBarkerCEmmanuelAOpioid-induced constipation: pathophysiology, clinical consequences, and managementGastroenterol Res Pract2014201416
   Web of Science ®Google Scholar
• TackJCorsettiMNaloxegol for the treatment of opioid-induced constipationExpert Rev Gastroenterol Hepatol20148885586125220391
   PubMed Web of Science ®Google Scholar
• CamilleriMDrossmanGWebsterLRDaviesANMaweGMEmerging treatment in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipationNeurogastroenterol Motil2014261386139525164154
   PubMed Web of Science ®Google Scholar
• GaertnerJSiemensWCamilleriMDefinitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic reviewJ Clin Gastroenterol201549191625356996
   PubMed Web of Science ®Google Scholar
• DavisMGamierPNew options in constipation managementCurr Oncol Rep2015175526449843
   PubMed Web of Science ®Google Scholar
• ArgoffCEBrennanMJCamilleriMConsensus recommendations of initiating prescription therapies for opioid-induced constipationPain Med2015162324233726582720
   PubMed Web of Science ®Google Scholar
• CoyneKSLoCasaleRJDattoCJSextonCCYeomanKTackJOpioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart reviewClinicoecon Outcomes Res2014626928124904217
   PubMedGoogle Scholar
• AbramowitzLBéziaudNCausséCChuberreBAllaertFPerrotSFurther validation of the psychometric properties of the bowel function index for evaluating opioid-induced constipation (OIC)J Med Econ201316121423144124102123
   PubMedGoogle Scholar
• BellTPanchalSMiaskowskiCBolgeSMilanovaTWilliamsonRThe prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient surveyPain Med2009101354218721170
   PubMed Web of Science ®Google Scholar
• OlesenADrewesAValidated tools for evaluating opioid-induced bowel dysfunctionAdv Ther201128427929421437762
   PubMed Web of Science ®Google Scholar
• GuptaSPatelJScopelJModyRImpact of constipation on opioid therapy management among long-term opioid users, based on a patient surveyJ Opioid Manag201511432533826312960
   PubMedGoogle Scholar
• HjalteFBerggrenABergendahlHHjortsbergCThe direct and indirect costs of opioid-induced constipationJ Pain Symptom Manage201040569670320727708
   PubMed Web of Science ®Google Scholar
• TarumiYWilsonMPSzafranOSpoonerGRRandomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patientsJ Pain Symptom Manage201345121322889861
   PubMed Web of Science ®Google Scholar
• CandyBJonesLGoodmanMLDrakeRTookmanALaxatives or methylnaltrexone for the management of constipation in palliative care patientsCochrane Database Syst Rev20111CD003448
   PubMed Web of Science ®Google Scholar
• AhmedzaiSHLeppartWJaneckiMLong-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer painSupport Care Cancer20152382383025218610
   PubMed Web of Science ®Google Scholar
• ThomasJKarverSCooneyGAMethylnaltrexone for opioid-induced constipation in advanced illnessN Engl J Med2008358222332234318509120
   PubMed Web of Science ®Google Scholar
• Entereg (alvimopan) [package insert]Lexington, MACubist Pharmaceuticals, Inc.2013
   Google Scholar
• Movantik™ (naloxegol) tablets [package insert]Product informationWilmington, DEAstraZeneca Pharmaceuticals LP92014
   Google Scholar
• EldonMASongDNeumannTANKTR-118 (oral PEG-naloxol), a PEGylated derivative of naloxone: demonstration of selective peripheral opioid antagonism after oral administration in preclinical modelsPoster presented at: 18th Annual Clinical Meeting of the American Academy of Pain Management927–302007Las Vegas, NV
   Google Scholar
• BuiKSheFSostekMThe effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegolJ Clin Pharmacol201454121375138224946021
   PubMed Web of Science ®Google Scholar
• CheyWDWebsterLSostekMLappalainenJBarkerPNTackJNaloxegol for opioid-induced constipation in patients with noncancer painN Engl J Med2014370252387239624896818
   PubMed Web of Science ®Google Scholar
• WebsterLCheyWDTackJLappalainenJDivaUSostekMRandomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipationAliment Pharmacol Ther201440777177925112584
   PubMed Web of Science ®Google Scholar
• GottfridssonCCarlsonGLappalainenJSostekMEvaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteersClin Ther201335121876188324238792
   PubMed Web of Science ®Google Scholar
• WebsterLDharSEldonMMasoukaLLappaliaininJSostekMA Phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patient with opioid-induced constipationPain20131541542155023726675
   PubMed Web of Science ®Google Scholar
• HolzerPNaloxegol increases frequency of bowel movements and combats inadequate response to laxativesEvid Based Med2015201525209526
   PubMedGoogle Scholar
• BuiKSheFSostekMThe effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegolJ Clin Pharmacol201454121368137424945932
   PubMed Web of Science ®Google Scholar
• BrunerHCAtayeeRSEdmondsKPBuckholzGTClinical utility of naloxegol in the treatment of opioid-induced constipationJ Pain Res2015828929426109876
   PubMed Web of Science ®Google Scholar